Evidence map›Paper›PMID 31046725›Full record

ArticleBMC public health2019

Influenza epidemiology and influenza vaccine effectiveness during the 2016-2017 season in the Global Influenza Hospital Surveillance Network (GIHSN).

Víctor Baselga-Moreno, Svetlana Trushakova, Shelly McNeil, Anna Sominina, Marta C Nunes, Anca Draganescu, Serhat Unal, Parvaiz Koul, Jan Kyncl, Tao Zhang and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 10 countries.

Víctor Baselga-MorenoFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020, Valencia, Spain.
Svetlana TrushakovaIvanovsky Institute of Virology FSBI "N.F. Gamaleya FRCEM" Ministry of Health, Moscow, Russian Federation.
Shelly McNeilCanadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Halifax, Canada.
Anna SomininaResearch Institute of Influenza, WHO National Influenza Centre of Russia, St. Petersburg, Russian Federation.
Marta C NunesMedical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Anca DraganescuNational Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest (INBI "Prof. Dr. Matei Bals"), București, Romania.
Serhat UnalTurkish Society of Internal Medicine, Ankara, Turkey.
Parvaiz KoulDepartment of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, India.
Jan KynclNational Institute of Public Health, Prague, Czech Republic.
Tao ZhangFudan University, Shanghai, China.
Ainagul KuatbayevaCenter for Sanitary-Epidemiological Expertise and Monitoring, Almaty, Kazakhstan.
Afif Ben-SalahPasteur Institute of Tunis, Tunis, Tunisia.
Elena BurtsevaIvanovsky Institute of Virology FSBI "N.F. Gamaleya FRCEM" Ministry of Health, Moscow, Russian Federation.
Joan Puig-BarberàFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020, Valencia, Spain.
Javier Díez-DomingoFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020, Valencia, Spain. jdiezdomingo@gmail.com.
Global Influenza Hospital Surveillance Network (GIHSN)
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESMinistry of Health of the Russian Federation · RUFudan University · CNIzaak Walton Killam Health Centre · CANational Institute of Public Health · CZNational Research Foundation · ZAResearch Institute of Influenza · RUSher-i-Kashmir Institute of Medical Sciences · INTurkish Society of Cardiology · TRUniversity College of Bahrain · BH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016-2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016-2017 influenza season.

methodsA RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = (1-aOR) × 100, where aOR is the adjusted Odds Ratio comparing cases and controls.

resultsAmong 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62-37.27. Vaccination seemed to confer better protection against influenza B and in people 2-4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59-5.76) comparing pregnant with non-pregnant women.

conclusionsVaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn't allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women.

Indexed as

Sentinel SurveillanceAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGlobal HealthHospitalizationHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesMaleInfluenza VaccinesEpidemiologyInfluenza virusSurveillanceVaccine effectiveness

Identifiers

PMID31046725
PMCPMC6498567
OpenAlexW2947728663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.